Treatment of a 54-Year-Old Male With Tumor-Stage Mycosis Fungoides
Source: CCO Interactive Case Challenges: Diagnosis and Treatment of Cutaneous T-Cell Lymphoma

Case Challenge

Francine Foss, MD, reviews optimal management of a highly functional patient presenting with de novo tumor-stage mycosis fungoides.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the quality-of-life and adverse effect issues involved in first-line treatment of a highly functional patient with tumor-stage mycosis fungoides and preexisting medical conditions
  • Describe the use of immunosuppressive vs nonimmunosuppressive approaches as second-line treatment for patients with tumor-stage mycosis fungoides
  • Discuss the use of targeted approaches to treatment in cutaneous T-cell lymphoma
 

Faculty

  • Francine Foss
    MD

Credit Information

  • Release Date:
    July 25, 2007
  • Expiration Date:
    July 24, 2008
  • Physicians:
    maximum of 0.5 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

 

Faculty

Francine Foss, MD


Professor of Medical Oncology
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

Francine Foss, MD, has reported serving on the Speaker’s Bureau for Merck.
 

Staff

Edward King, MA


Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no significant financial relationships to disclose.
 

Andrew D. Bowser, ELS


Editorial Director, Hematology/Oncology
Clinical Care Options, LLC

Andrew D. Bowser has no significant financial relationships to disclose.
 

Robert S. Mocharnuk, MD


Contributing Editor

Robert S. Mocharnuk, MD, has no significant financial relationships to disclose.
 

Anthony Dvarskas, PhD


Associate Managing Editor, Hematology/Oncology
Clinical Care Options, LLC

Anthony Dvarskas has no significant financial relationships to disclose.
 

Jim Mortimer, 


Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no significant financial relationships to disclose.
 

The following PIM clinical content reviewers, Linda Graham, RN; Jan Hixon, RN; and Trace Hutchison, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute of Medicine (PIM) and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This activity is designed for medical dermatologists, oncologists, and other healthcare professionals who treat patients with cutaneous T-cell lymphoma.


Goal

The goal of this activity is to enhance the quality of care provided by physicians treating patients with cutaneous T-cell lymphoma by providing up-to-date information on patient management through challenging case scenarios.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the quality-of-life and adverse effect issues involved in first-line treatment of a highly functional patient with tumor-stage mycosis fungoides and preexisting medical conditions
  • Describe the use of immunosuppressive vs nonimmunosuppressive approaches as second-line treatment for patients with tumor-stage mycosis fungoides
  • Discuss the use of targeted approaches to treatment in cutaneous T-cell lymphoma
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by an educational grant from Merck & Co., Inc..

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 25, 2007, through July 24, 2008:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.